

PIMSH 15 Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center - Avoidance of Overuse

In this lesson, you will learn the documentation for MIPS **#PIMSH15: Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center - Avoidance of Overuse** quality measure.

This is an inverse measure, a lower score indicates better performance.

- **Low-emetic-risk antineoplastic agents** - Adults treated with low-emetic-risk antineoplastic agents should be offered a single dose of a 5-HT3 receptor antagonist or a single 8-mg dose of dexamethasone before *their first-ever antineoplastic treatment* (Type: informal consensus, benefits outweigh harms; Evidence quality: low, Strength of recommendation: moderate).
- **Minimal-emetic-risk antineoplastic agents** - Adults treated with minimal-emetic-risk antineoplastic agents should not be offered routine antiemetic prophylaxis *before their first-ever antineoplastic treatment* (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: moderate).

Numerator note: For the purposes of this measure, an anti-emetic order will be considered as “intent to administer” and will be included in the numerator even if not administered.

The screenshot shows the iKnowMed interface for a patient named Quincy Hart (69 / M). The top navigation bar includes icons for a person, a dollar sign, a heart, and an envelope, along with the patient's name and date of birth (DOB: 12/07/1). Below the navigation bar are tabs for 'Chart Summary', 'Clinical Profile', and 'Flowsheet'. Under the 'Orders' tab, there are sub-tabs for 'New Orders (0)', 'Medications (0)', 'Regimens (0)', and 'Orders'. The 'Regimens (0)' tab is currently selected. Below the tabs is the 'Regimen Search' section, which includes a 'Diagnosis/Problem' dropdown menu with 'Bone metastasis (C79.51 Se)' selected. To the right of the dropdown is a blue button labeled 'SEARCH FOR REGIMENS', which is highlighted with a red box. A yellow circle with the number '1' points to this button. Below the search section is a section for 'Additional Data' and a 'Regimen History' link at the bottom.

1. In the **Orders** tab, go to **Regimens**.

iKnowMedSM Generation 2

Select the diagnosis from the drop-down and click SEARCH FOR REGIMENS.

Regimen Type:

Show Definitions

Chemotherapy

Immunotherapy

Targeted therapy

Hormone

Supportive care

Other

2

CANCEL

2. Select the appropriate **Regimen Type**.

Medical Info		Filter Chemotherapies by:		CLEAR
BEACOPP (Escalated) Q21D	unknown	high (60-90%)	SELECT	
Belimumab IV Q28D	unknown	minimal (<10%)	SELECT	
Belinostat D1-5 Q21D	unknown	low (10-29%)	SELECT	
Belumosudil Q30D	wbc gf not applicable	low (10-29%)	SELECT	
Belzutifan Q30D	low (<10%)	minimal (<10%)	SELECT	
Bendamustine (90 mg/m2) D1,2 Q28D (CAR T-cell Therapy Lymphodepletion)	low (<10%)	moderate-high (60-90%)	SELECT	
Bendamustine D1,2 + Rituximab IV (BR) Q28D	low (<10%)	moderate-high (60-90%)	SELECT	
Bendamustine D1,2 + Rituximab IV fb SQ (BR) Q28D	low (<10%)	moderate-high (60-90%)	SELECT	
Bendamustine D1,2 + Rituximab IV Q28D (CLL Frontline: BR 90 mg/m2)	low (<10%)	moderate-high (60-90%)	SELECT	
Bendamustine D1,2 + Rituximab IV Q28D (CLL Relapsed: BR 70 mg/m2)	low (<10%)	moderate-high (60-90%)	SELECT	
Bendamustine D1,2 Q21D	low (<10%)	moderate-high (60-90%)	SELECT	

3. Select the desired regimen.



The emetogenic risk is provided for each regimen as low, minimal, moderate, or high.

iKnowMedSM Generation 2

Regimen Name * (as it will appear on the flowsheet)
Belinostat D1-5 Q21D

Cycle * 21 **Starting On *** 1 1 **Start Date** 06/01/2023
Length # of Cycles Cycle Day

Patient Height / Weight (missing) **BSA** (DuBois And DuBois) 0.00 m2 **ADD NEW VITAL SIGNS**

Associated Problem * Bone metastasis (C) **Line of Therapy *** Select **Stage** Select **Treatment Intent** Select


Regimen Comments **Instructions to Ordering Provider**

Emetic potential: Emetic Risk: Low (10-29%)
FN potential: Unknown
References
Patient Education Belinostat
Estimated Infusion time 1 hour, 0 minutes
☒ **Requires Financial Approval**
Ordered from Location * Central Region-Boulder Clin
Perform Location
☒ Unspecified-to be completed by Scheduler
☐ Specified
Type Select **Location** Search Locations

4

OK CANCEL

4. Complete the Regimen Details and click OK.

 While reviewing the regimen orders, additional medications can be added. For low to minimal emetogenic risk regimens, avoid administering inappropriate pre-treatment antiemetic therapy.

New Orders (0)

Medications (0)

Regimens (16)

Order Review

Order History

Drafts

ALERTS

Belinostat D1-5 Q21D

ADD TREATMENT GROUP

IMMUNOTHERAPY

Add an Order

Search Orderables

Dose

Calculated Dose

Schedule

Belinostat IV

(1000 mg/m2; BSA: 0 m2)

Belinostat IV intravenously Piggyback once. **Admin over:** 30 minutes **Admix fluid:** 0.9 % Sodium Chloride **Volume:** 250 mL **Instructions:** Reduce the starting dose of Belinostat to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele. If infusion site pain or other symptoms potentially attributable to the infusion occur, the infusion time may be extended to 45 minutes. Infuse through a 0.22 micron in-line filter.

1000 mg/m2

Adjust Dose

C1D1,C1D2,C1D3,C1D4,C1D5,C2D1,C2D2,C2D3,C2D4,...

PREMEDICATIONS

Add an Order

Search Orderables

Dose

Calculated Dose

Schedule

Granisetron IV

Granisetron IV 1000 mcg intravenously once.

1000 mcg

C1D1,C1D2,C1D3,C1D4,C1D5,C2D1,C2D2,C2D3,C2D4,...

Granisetron Oral

Granisetron Oral 1 mg Tablet 2 tablet orally every day.

2 mg

C1D1,C1D2,C1D3,C1D4,C1D5,C2D1,C2D2,C2D3,C2D4,...

Granisetron Oral

Granisetron Oral 1 mg Tablet 2 tablet orally every day as needed. **Dispense:** 6 Tablet **Refills:** 0 **Allow Substitution**

2 mg

C1D1,C2D1,C3D1,C4D1,C5D1,C6D1

Ondansetron IV

Ondansetron IV 8 mg intravenously once.

8 mg

C1D1,C1D2,C1D3,C1D4,C1D5,C2D1,C2D2,C2D3,C2D4,...

Dexamethasone IV

Dexamethasone IV 10 mg intravenously Piggyback once. **Admin over:** 20 minutes **Instructions:** Mix in 50 mL NS.

10 mg

C1D1,C1D2,C1D3,C1D4,C1D5,C2D1,C2D2,C2D3,C2D4,...

Dexamethasone Oral

Dexamethasone Oral 4 mg tablet 2 tablet orally every day. Take 8 mg PO on Days 2-4. **Dispense:** 10 Tablet **Refills:** 0 **Allow Substitution**

8 mg

C1D1,C2D1,C3D1,C4D1,C5D1,C6D1

Prochlorperazine IV

Prochlorperazine IV 10 mg intravenously Push once. **Admin over:** 10 minutes

10 mg

C1D1,C1D2,C1D3,C1D4,C1D5,C2D1,C2D2,C2D3,C2D4,...

Prochlorperazine Oral

Prochlorperazine Oral 10 mg Tablet 1 tablet orally every 6 hours as needed for nausea. **Dispense:** 30 Tablet **Refills:** 0 **Allow Substitution**

10 mg


C1D1,C2D1,C3D1,C4D1,C5D1,C6D1

REVIEW / SAVE

5

5. Once complete, click **REVIEW/SAVE**.

iKnowMedSM Generation 2



6. Click **SIGN ORDERS** to complete.

This concludes the lesson for the MIPS **#PIMSH15: Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center - Avoidance of Overuse** quality measure.